Article Text

Download PDFPDF
Further evidence to support weight loss and lifestyle interventions for people taking antipsychotic medications
  1. Tanya Park,
  2. Bernadette Workun
  1. Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada
  1. Correspondence to Dr Tanya Park; tanya.park{at}

Statistics from

ABSTRACT FROM: Green CA, Yarborough BJ, Leo MC, et al. The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial. Am J Psychiatry 2015;172:71–81.

What is already known on this topic

Increasing weight is the leading risk factor for many life-shortening illnesses such as cardiovascular disease, stroke and diabetes.1 Individuals with serious mental illness (SMI) such as schizophrenia are at increased risk of medical comorbidities, including metabolic syndrome, leading to an increased risk for cardiovascular disease and diabetes. As a result, life expectancy is shorter than those in the general population.2 The elevated cardiometabolic risks can be due to inadequate nutrition, limited access to medical care, sedentary lifestyle, smoking and treatments such as prescription of antipsychotic medications. Healthy lifestyle interventions developed specifically for people with mental illness are essential in the treatment and prevention of reduction of weight gain and risk of diabetes.

Methods of the study

This study was a multisite parallel two-arm …

View Full Text


  • Competing interests None declared.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.